EpiCast Report: Brain Cancer - Epidemiology Forecast to 2024

News provided by

Jan 05, 2016, 03:19 ET

LONDON, Jan. 5, 2016 /PRNewswire/ -- EpiCast Report: Brain Cancer - Epidemiology Forecast to 2024

Summary

Primary brain cancer is defined as a malignant neoplasm that originates in the central nervous system (CNS), which consists of the brain and spinal cord, including the brain stem (NCI, 2015). The American Brain Tumor Association (ABTA) reports that there are over 120 different types of malignant and benign brain tumors, (ABTA, 2014). The type and severity of a brain tumor is defined by the cells from which the tumor originated, as well as by the proliferative potential of the abnormal growth, and only those tumors that are malignant are designated as cancer (NCI, 2015). Primary brain tumors are those that start in the brain and may, in time, migrate elsewhere in the body, while metastatic brain tumors are those that start elsewhere in the body and migrate to the brain or other parts of the CNS.

In the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan), GlobalData epidemiologists forecast that the diagnosed incident cases of brain cancer will increase from 55,084 cases in 2014 to 62,226 cases in 2024, at an Annual Growth Rate (AGR) of 1.30%. The US will have the highest number of diagnosed incident cases of brain cancer among the 7MM throughout the forecast period. The five-year diagnosed prevalent cases of brain cancer are also expected to increase from 84,704 cases in 2014 to 89,984 cases in 2024, at an AGR of 0.62%. The US will have the highest number of five-year diagnosed prevalent cases of brain cancer in 2014 and 2024, at 42,104 cases and 46,401 cases, respectively.

This report provides an overview of the risk factors, comorbidities, and the global and historical trends for brain cancer in the 7MM. It includes a 10-year epidemiological forecast for the diagnosed incident cases and the five-year diagnosed prevalent cases of brain cancer, each segmented by sex and age. Additionally, it includes a forecast for the diagnosed incident cases of brain cancer, segmented by type (glioblastoma, meningioma, ependymoma, oligodendroglioma, and CNS lymphoma). This forecast for brain cancer includes only primary malignant brain tumors originating in the CNS (ICD-10 codes C70-C72).

Scope

- The brain cancer EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical trends for brain cancer in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). This report includes a 10-year epidemiological forecast for the diagnosed incident cases and the five-year diagnosed prevalent cases of brain cancer, each segmented by sex and age. Additionally, it includes a forecast for the diagnosed incident cases of brain cancer, segmented by type (glioblastoma, meningioma, ependymoma, oligodendroglioma, and CNS lymphoma).
- The brain cancer epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The brain cancer EpiCast report will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global brain cancer market.
- Quantify patient populations in the global brain cancer market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for brain cancer therapeutics in each of the markets covered.
Download the full report: https://www.reportbuyer.com/product/3524428/

About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
http://www.reportbuyer.com